http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 28 Jul 2026 16:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. </p><p> <b>Arcturus Therapeutics Second Quarter 2026 Earnings Conference Call</b> </p><ul class="bwlistdisc"> <li> Thursday, Aug 6, 2026, at 4:30 p.m. ET </li> <li> Domestic: 1-800-347-6865 </li> <li> International: 1-203-518-9757 </li> <li> Conference ID: ARCTURUS </li> <li> Webcast: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1769554%26tp_key%3D96c7f551a6&amp;esheet=54578757&amp;newsitemid=20260728520662&amp;lan=en-US&amp;anchor=Link&amp;index=1&amp;md5=fe00d6b320171f46954ae91461348266" shape="rect">Link</a> </li> </ul><p> <b>About Arcturus</b> </p><p> Founded in 2013 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html Tue, 28 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. </p><p> <b>Arcturus Therapeutics Second Quarter 2026 Earnings Conference Call</b> </p><ul class="bwlistdisc"> <li> Thursday, Aug 6, 2026, at 4:30 p.m. ET </li> <li> Domestic: 1-800-347-6865 </li> <li> International: 1-203-518-9757 </li> <li> Conference ID: ARCTURUS </li> <li> Webcast: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1769554%26tp_key%3D96c7f551a6&amp;esheet=54578757&amp;newsitemid=20260728520662&amp;lan=en-US&amp;anchor=Link&amp;index=1&amp;md5=fe00d6b320171f46954ae91461348266" shape="rect">Link</a> </li> </ul><p> <b>About Arcturus</b> </p><p> Founded in 2013 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html Tue, 28 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. </p><p> <b>Arcturus Therapeutics Second Quarter 2026 Earnings Conference Call</b> </p><ul class="bwlistdisc"> <li> Thursday, Aug 6, 2026, at 4:30 p.m. ET </li> <li> Domestic: 1-800-347-6865 </li> <li> International: 1-203-518-9757 </li> <li> Conference ID: ARCTURUS </li> <li> Webcast: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1769554%26tp_key%3D96c7f551a6&amp;esheet=54578757&amp;newsitemid=20260728520662&amp;lan=en-US&amp;anchor=Link&amp;index=1&amp;md5=fe00d6b320171f46954ae91461348266" shape="rect">Link</a> </li> </ul><p> <b>About Arcturus</b> </p><p> Founded in 2013 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html Tue, 28 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. </p><p> <b>Arcturus Therapeutics Second Quarter 2026 Earnings Conference Call</b> </p><ul class="bwlistdisc"> <li> Thursday, Aug 6, 2026, at 4:30 p.m. ET </li> <li> Domestic: 1-800-347-6865 </li> <li> International: 1-203-518-9757 </li> <li> Conference ID: ARCTURUS </li> <li> Webcast: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1769554%26tp_key%3D96c7f551a6&amp;esheet=54578757&amp;newsitemid=20260728520662&amp;lan=en-US&amp;anchor=Link&amp;index=1&amp;md5=fe00d6b320171f46954ae91461348266" shape="rect">Link</a> </li> </ul><p> <b>About Arcturus</b> </p><p> Founded in 2013 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html Tue, 28 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html si-local-file:///var/storage/secattach/20260702/26723891.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html Thu, 02 Jul 2026 07:06:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html si-local-file:///var/storage/secattach/20260702/26723891.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html Thu, 02 Jul 2026 07:06:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html <p>Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has entered into a manufacturing and clinical research collaboration with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, an investigational mRNA therapy for cystic fibrosis, according to a press release from the San Diego-based company.</p> <p>Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services through its Accelerator™ Drug Development platform. If Phase 2 results are positive, Arcturus expects to conduct its Phase 3 program through Thermo Fisher's PPD™ clinical research business.</p> <p>Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html Thu, 02 Jul 2026 07:00:12 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html <p>Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has entered into a manufacturing and clinical research collaboration with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, an investigational mRNA therapy for cystic fibrosis, according to a press release from the San Diego-based company.</p> <p>Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services through its Accelerator™ Drug Development platform. If Phase 2 results are positive, Arcturus expects to conduct its Phase 3 program through Thermo Fisher's PPD™ clinical research business.</p> <p>Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html Thu, 02 Jul 2026 07:00:12 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html <p>Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has entered into a manufacturing and clinical research collaboration with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, an investigational mRNA therapy for cystic fibrosis, according to a press release from the San Diego-based company.</p> <p>Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services through its Accelerator™ Drug Development platform. If Phase 2 results are positive, Arcturus expects to conduct its Phase 3 program through Thermo Fisher's PPD™ clinical research business.</p> <p>Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html Thu, 02 Jul 2026 07:00:12 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html <p>Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has entered into a manufacturing and clinical research collaboration with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, an investigational mRNA therapy for cystic fibrosis, according to a press release from the San Diego-based company.</p> <p>Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services through its Accelerator™ Drug Development platform. If Phase 2 results are positive, Arcturus expects to conduct its Phase 3 program through Thermo Fisher's PPD™ clinical research business.</p> <p>Subject to regulatory approval of ARCT-032, Thermo Fisher will receive exclusive commercial manufacturing http://www.streetinsider.com/Corporate+News/Arcturus+and+Thermo+Fisher+partner+on+cystic+fibrosis+mRNA+therapy/26723845.html Thu, 02 Jul 2026 07:00:12 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html <p class="bwalignc"> <i>Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. </p><p> The collaboration will leverage Thermo Fisher's Accelerator™ Drug Development solutions, combining manufacturing and clinical research capabilities to support Phase 3 development through potential commercialization. Thermo Fisher http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Strategic+Collaboration+with+Thermo+Fisher+Scientific+to+Advance+ARCT-032+for+Cystic+Fibrosis/26723831.html Thu, 02 Jul 2026 07:00:00 -0400 A.50208735 ARCT O.02594693 O.41325150 http://www.streetinsider.com/New+Coverage/Freedom+Broker+Starts+Arcturus+Therapeutics+%28ARCT%29+at+Buy/26723229.html <p>Freedom Broker initiates coverage on Arcturus Therapeutics (NASDAQ: ARCT) with a Buy rating and a price target of $27.00.</p><p>For an analyst ratings summary and ratings history on Arcturus Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=ARCT">click here</a>. For more ratings news on Arcturus Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=ARCT&amp;type=analyst">click here</a>.</p><p>Shares of Arcturus Therapeutics closed at $6.89 yesterday.</p> http://www.streetinsider.com/New+Coverage/Freedom+Broker+Starts+Arcturus+Therapeutics+%28ARCT%29+at+Buy/26723229.html Thu, 02 Jul 2026 05:37:25 -0400 ARCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+BARLOW+JAMES+F/26648391.html si-local-file:///var/storage/secattach/20260615/26648391.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+BARLOW+JAMES+F/26648391.html Mon, 15 Jun 2026 17:02:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+BARLOW+JAMES+F/26648391.html si-local-file:///var/storage/secattach/20260615/26648391.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcturus+Therapeutics+++++For%3A+Jun+05++Filed+by%3A+BARLOW+JAMES+F/26648391.html Mon, 15 Jun 2026 17:02:00 -0400 ARCT O.41325150